Arigo is proud to announce that our HMGB1 ELISA Kit (ARG81310) was cited again. Kim et al. used this ELISA kit to measure the exosomal HMGB1 levels released from non-irradiated and gamma-irradiated melanoma cancer cells and demonstrated that exosomal HMGB1 stimulates immunogenic cell death (ICD).
Immunogenic cell death (ICD)
ICD is a form of cell death resulting in an activation of immune response. ICD is triggered by damage-associated molecular patterns (DAMPs) such as exposure of calreticulin (CRT) at plasma membrane and release of HMGB1 and ATP. DAMPs contribute to the maturation of dendritic cells (DCs), which present antigens to CD8+ T cells, leading to activation of adaptive immunity.
Accumulated reports reveal that irradiation or chemotherapy not only results to cancer cell death but also induces immunological anti-tumor responses via ICD. It is believed that the combination of ICD induction and other anti-cancer therapy is a promising approach for cancer treatment.
HMGB1, a critical marker of ICD
HMGB1 is one of DAMPs and important for ICD. The released HMGB1 binds to TLR4 to induce DC maturation, antigen presentation and subsequent cytotoxicity mediated by CD8+ T cells.
Arigo offers quality antibodies and ELISA kits and to accelerate the research of ICD.